Displaying publications 1 - 20 of 76 in total

Abstract:
Sort:
  1. Kataria N, Bhushan D, Gupta R, Rajendran S, Teo MYM, Khoo KS
    Environ Pollut, 2022 Dec 15;315:120319.
    PMID: 36183872 DOI: 10.1016/j.envpol.2022.120319
    Bisphenol-A (BPA) is a type of endocrine disrupting compound (EDC) that is being widely used in the production of polycarbonate and epoxy resins. In the last few years, human exposure to BPA has been extensively high due to the continuous increment in the Annual Growth Rate (AGR) of the BPA global market. The presence and transportation of BPA in the environment could cause serious damage to aquatic life and human health. This paper reviewed the literature on the exposure and toxicity mechanisms of BPA and advanced analytical techniques for the detection of BPA in the environment and human beings. The study indicated that BPA can cause damaging effects on numerous tissues and organs, including the reproductive system, metabolic dysfunction, respiratory system, immune system and central nervous system. On the basis of reported studies on animals, it appears that the exposure of BPA can be carcinogenic and responsible for causing a variety of cancers like ovarian cancer, uterine cancer, prostate cancer, testicular cancer, and liver cancer. This review paper focused mainly on the current progress in BPA removal technologies within last ten years (2012-2022). This paper presents a comprehensive overview of individual removal technologies, including adsorption, photocatalysis/photodegradation, ozonation/advance oxidation, photo-fenton, membranes/nanofilters, and biodegradation, along with removal mechanisms. The extensive literature study shows that each technology has its own removal mechanism and their respective limitations in BPA treatment. In adsorption and membrane separation process, most of BPA has been treated by electrostatic interaction, hydrogen boning and π-π interations mechanism. Whereas in the degradation mechanism, O* and OH* species have played a major role in BPA removal. Some factors could alter the removal potential and efficiency of BPA removal. This review paper will provide a useful guide in providing directions for future investigation to address the problem of BPA-containing wastewater treatment.
    Matched MeSH terms: Benzhydryl Compounds/analysis; Benzhydryl Compounds/toxicity
  2. EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol, 2024 Jan;12(1):51-60.
    PMID: 38061372 DOI: 10.1016/S2213-8587(23)00322-4
    BACKGROUND: The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.

    METHODS: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110.

    FINDINGS: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1).

    INTERPRETATION: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease.

    FUNDING: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.

    Matched MeSH terms: Benzhydryl Compounds/pharmacology; Benzhydryl Compounds/therapeutic use
  3. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al.
    N Engl J Med, 2023 Jan 12;388(2):117-127.
    PMID: 36331190 DOI: 10.1056/NEJMoa2204233
    BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.

    METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to <10 ml per minute per 1.73 m2, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.

    RESULTS: A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P<0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P = 0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups.

    CONCLUSIONS: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).

    Matched MeSH terms: Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/therapeutic use
  4. Mengting Z, Kurniawan TA, Yanping Y, Avtar R, Othman MHD
    Mater Sci Eng C Mater Biol Appl, 2020 Mar;108:110420.
    PMID: 31924000 DOI: 10.1016/j.msec.2019.110420
    Bisphenol A (BPA) is a refractory pollutant presents in water body that possesses serious threats to living organisms. To deal with it, we investigate and evaluate the effectiveness of GO@BiOI/Bi2WO6 composite as a novel photocatalyst for BPA removal from aqueous solutions under UV-vis irradiation. To enhance its removal for BPA, the surface of BiOI/Bi2WO6 is modified with graphene oxide (GO). This composite is named as 'GO@BiOI/Bi2WO6'. Changes in its physico-chemical properties after surface modification with GO are characterized by XRD, FTIR, FESEM-EDS, XPS, PL, and BET methods. Optimized conditions of BPA degradation by the composite are determined under identical conditions. Photodegradation pathways of BPA and its removal mechanisms by the same composite are presented. It is obvious that the GO@BiOI/Bi2WO6 has demonstrated its potential as a promising photocatalyst for BPA removal under UV-vis irradiation. About 81% of BPA removal is attained by the GO@BiOI/Bi2WO6 under optimized conditions (10 mg/L of BPA, 0.5 g/L of dose, pH 7 and 5 h of reaction time). The oxidation by-products of BPA degradation include p-hydroquinone or 4-(1-hydroxy-1-methyl-ethyl)-phenol. In spite of its performance, the treated effluents are still unable to meet the maximum discharge limit of <1 mg/L set by national legislation. Therefore, subsequent biological processes are essential to maximize its biodegradation in the wastewater samples before their discharge into waterbody.
    Matched MeSH terms: Benzhydryl Compounds/chemistry*
  5. Prabhu NB, Adiga D, Kabekkodu SP, Bhat SK, Satyamoorthy K, Rai PS
    Environ Toxicol Pharmacol, 2022 Nov;96:104010.
    PMID: 36334871 DOI: 10.1016/j.etap.2022.104010
    Bisphenol A (BPA) mimics estrogen and consequently suspected to be detrimental to female reproductive system. Biomonitoring confirms the BPA burden in body leading to a complex condition called polycystic ovarian syndrome (PCOS) which is frequently attributed to female infertility. Due to unclear precise molecular pathomechanisms of BPA in PCOS, we intend to examine the molecular mechanisms of the reproductive, endocrine, mitochondrial features, and cellular senescence in BPA-treated rats. We analyzed vaginal smears and ovarian follicles using microscope, assessed sex hormones by ELISA, analyzed BPA target gene expression by semi-quantitative RT-PCR, assessed senescence induction by β-galactosidase staining and immunofluorescence in BPA-treated rats. Our data showed hormonal imbalance, impaired folliculogenesis, abnormal expression patterns of target genes, CDKN2A overexpression and enhanced ROS levels in BPA-treated rats. This study provides insights on the effects of BPA exposure on ovulatory, hormonal, mitochondrial dysfunction, and senescence that benefit in better understanding of PCOS induced by BPA.
    Matched MeSH terms: Benzhydryl Compounds/toxicity
  6. M Hanif A, Bushra R, Ismail NE, Bano R, Abedin S, Alam S, et al.
    Pak J Pharm Sci, 2021 May;34(3(Supplementary)):1081-1087.
    PMID: 34602436
    The current investigation is based on efficient method development for the quantification of empagliflozin in raw and pharmaceutical dosage forms, as no pharmacopoeial method for the drug is available so far. The developed analytical method was validated as per ICH guidelines. C18 column with mobile phase (pH 4.8) consisted of 0.1% trifluoroacetic acid solution and acetonitrile (70:30 v/v) was used for drug analysis. The calibration plot showed good linear regression (r2>0.999) over the concentration of 0.025-30 μg mL-1. The LOD and LOQ were found to be 0.020 μg mL-1 and 0.061 μg mL-1, respectively. The percentage recovery was estimated between 98.0 to 100.13%. Accuracy and precision data were found to be less than 2%, indicating the suitability of method for routine analysis in pharmaceutical industries. Moreover, the drug solution was found to be stable in refrigerator and ambient room temperature with mean % accuracy of >98%. Empagliflozin contents were also tested in both the raw API and marketed tablet brands using this newly developed method. The mean assay of raw empagliflozin and tablet brands were ranged from 99.29%±1.12 to 100.95%±1.69 and 97.18%±1.59 to 98.92%±1.00 respectively. Based on these findings, the present investigated approach is suitable for quantification of empagliflozin in raw and pharmaceutical dosage forms.
    Matched MeSH terms: Benzhydryl Compounds/analysis*
  7. Sunasee S, Wong KT, Lee G, Pichiah S, Ibrahim S, Park C, et al.
    Environ Sci Pollut Res Int, 2017 Jun;24(18):15488-15499.
    PMID: 28512708 DOI: 10.1007/s11356-017-9124-0
    In this study, bisphenol A (BPA) removal by sonophotocatalysis coupled with commercially available titanium dioxide (TiO2, P25) was assessed in batch tests using energy-based advanced oxidation combining ultrasound (US) and ultraviolet (UV). The kinetics of BPA removal were systematically evaluated by changing operational parameters, such as US frequency and power, mechanical stirring speed, and temperature, but also comparison of single and coupled systems under the optimum US conditions (35 kHz, 50 W, 300 rpm stirring speed, and 20 °C). The combination of US/UV/P25 exhibited the highest BPA removal rate (28.0 × 10-3 min-1). In terms of the synergy index, the synergistic effect of sonophotocatalysis was found to be 2.2. This indicated that sonophotocatalysis has a considerably higher removal efficiency than sonocatalysis or photocatalysis. The removal of BPA was further investigated to identify BPA byproducts and intermediates using high-performance liquid chromatography-mass spectrometry. Five main intermediates were formed during sonophotocatalytic degradation, and complete removal of BPA and its intermediates was obtained after 3 h of operation. The degradation pathway of BPA by sonophotocatalysis was also elucidated.
    Matched MeSH terms: Benzhydryl Compounds/chemistry*
  8. Zainuddin AH, Roslan MQJ, Razak MR, Yusoff FM, Haron DEM, Aris AZ
    Mar Pollut Bull, 2023 Jul;192:115019.
    PMID: 37201347 DOI: 10.1016/j.marpolbul.2023.115019
    Bisphenol analogues are prevalent globally because of rampant usage and imprecise processing techniques, prompting alerts about environmental and health hazards. The method employed in this study by solid phase extraction (SPE) and liquid chromatography-tandem quadrupole mass spectrometer (LC-MS/MS) for both quantification and qualitative analysis of the bisphenol compounds in the surface water samples. The coastal and estuarine surface water of Port Dickson and Lukut ranges from 1.32 ng/L to 1890.51 ng/L of bisphenol analogues. BPF mean concentration at 1143.88 ng/L is the highest, followed by BPA and BPS at 59.01 ng/L and 10.96 ng/L, respectively. Based on RQm for bisphenol analogues, the highest for BPF at 2.49 (RQ > 1, high risk), followed by BPS at 0.12 (0.1 
    Matched MeSH terms: Benzhydryl Compounds/analysis
  9. Sukatis FF, Looi LJ, Lim HN, Abdul Rahman MB, Mohd Zaki MR, Aris AZ
    Environ Pollut, 2024 Jan 15;341:122980.
    PMID: 37992953 DOI: 10.1016/j.envpol.2023.122980
    The presence of emerging water pollutants such as endocrine-disrupting compounds (EDCs), including 17-ethynylestradiol (EE2), bisphenol A (BPA), and perfluorooctanoic acid (PFOA), in contaminated water sources poses significant environmental and health challenges. This study aims to address this issue by investigating the efficiency of novel calcium-based metal-organic frameworks, known as mixed-linker calcium-based metal-organic frameworks (Ca-MIX), in adsorbing these endocrine-disrupting compounds. This study analyzed the influence of influent concentration, bed height, and flow rate on pollutant removal, with bed height emerging as a crucial factor. From the breakthrough curves, it was determined that the column maximum adsorption capacities followed the order of 17-ethynylestradiol (101.52 μg/g; 40%) > bisphenol A (99.07 μg/g; 39%) > perfluorooctanoic acid (81.28 μg/g; 32%). Three models were used to predict the adsorption process, with the Yan model outperforming the other models. This suggests the potential of mixed-linker calcium-based metal-organic frameworks for removing endocrine-disrupting compounds from water, using the Yan model as an effective predictor. Overall, this study provides valuable insights for the development of effective water treatment methods using mixed-linker calcium-based metal-organic frameworks to remove endocrine-disrupting compounds from contaminated water sources.
    Matched MeSH terms: Benzhydryl Compounds/analysis
  10. Aziz A, Agamuthu P, Fauziah SH
    Waste Manag Res, 2018 Oct;36(10):975-984.
    PMID: 30058954 DOI: 10.1177/0734242X18790360
    Landfill leachate contain persistent organic pollutants (POPs), namely, bisphenol A (BPA) and 2,4-Di-tert-butylphenol, which exceed the permissible limits. Thus, such landfill leachate must be treated before it is released into natural water courses. This article reports on investigations about the removal efficiency of POPs such as BPA and 2,4-Di-tert-butylphenol from leachate using locust bean gum (LBG) in comparison with alum. The vital experimental variables (pH, coagulant dosage and stirring speed) were optimised by applying response surface methodology equipped with the Box-Behnken design to reduce the POPs from leachate. An empirical quadratic polynomial model could accurately model the surface response with R2 values of 0.928 and 0.954 to reduce BPA and 2,4-Di-tert-butylphenol, respectively. Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM) were performed on treated flocs for further understanding. FTIR analysis revealed that the bridging of pollutant particles could be due to the explicit adsorption and bridging via hydrogen bonding of a coagulation mechanism. SEM micrographs indicated that the flocs produced by LBG have a rough cloudy surface and numerous micro-pores compared with alum, which enabled the capture and removal of POPs from leachate. Results showed that the reduction efficiencies for BPA and 2,4-Di-tert-butylphenol at pH 7.5 were 76% and 84% at LBG dosage of 500 mg·L-1 and 400 mg·L-1, respectively. Coagulant dosage and pH variation have a significant effect on POPs reduction in leachate. Coagulation/flocculation using LBG could be applied for POPs reduction in leachate as a pre-treatment prior to advanced treatments.
    Matched MeSH terms: Benzhydryl Compounds
  11. Balakumar P, Sundram K, Dhanaraj SA
    Pharmacol Res, 2014 Apr;82:34-9.
    PMID: 24705156 DOI: 10.1016/j.phrs.2014.03.008
    Diabetes mellitus is a greatly challenging disease of the 21 century, and the mortality rate due to this insidious disease is increasing worldwide in spite of availability of effective oral hypoglycemic agents. Satisfactory management of glycemic control in patients afflicted with type 2 diabetes mellitus (T2DM) remains a major clinical challenge. Identification of potential pharmacological target sites is therefore continuing as an integral part of the diabetic research. The sodium-glucose co-transporter type 2 (SGLT2) expressed in the renal proximal tubule plays an essential role in glucose reabsorption. Pharmacological blockade of SGLT2 prevents glucose reabsorption and subsequently induces the elimination of filtered glucose via urine, the process is known as 'glucuresis'. Dapagliflozin is a selective inhibitor of SGLT2. The US FDA approved dapagliflozin in January 2014 to improve glycemic control along with diet and exercise in adult patients afflicted with T2DM. It has a potential to decrease glycated hemoglobin and to promote weight loss. Although the mechanism of action of dapagliflozin is not directly linked with insulin or insulin sensitivity, reduction of plasma glucose by dapagliflozin via induction of glucosuria could improve muscle insulin sensitivity. Moreover, dapagliflozin could cause diuresis and subsequently fall in blood pressure. In addition to general discussion on the pharmacology of dapagliflozin, we propose in this review the possibilities of dual antidiabetic effect of dapagliflozin and its possible additional beneficial actions in hypertensive-obese-T2DM patients through its indirect blood pressure-lowering action and reduction of body calories and weight. Long-term clinical studies are however needed to clarify this contention.
    Matched MeSH terms: Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/pharmacokinetics; Benzhydryl Compounds/pharmacology*; Benzhydryl Compounds/therapeutic use
  12. Al Azzam KM, Saad B, Aboul-Enein HY
    Electrophoresis, 2010 Sep;31(17):2957-63.
    PMID: 20690150 DOI: 10.1002/elps.201000266
    Binding constants for the enantiomers of modafinil with the negatively charged chiral selector sulfated-β-CD (S-β-CD) using CE technique is presented. The calculations of the binding constants employing three different linearization plots (double reciprocal, X-reciprocal and Y-reciprocal) were performed from the electrophoretic mobility values of modafinil enantiomers at different concentrations of S-β-CD in the BGE. The highest inclusion affinity of the modafinil enantiomers were observed for the S-enantiomer-S-β-CD complex, in agreement with the computational calculations performed previously. Binding constants for each enantiomer-S-β-CD complex at different temperatures, as well as thermodynamic parameters for binding, were calculated. Host-guest binding constants using the double reciprocal fit showed better linearity (r(2)>0.99) at all temperatures studied (15-30°C) and compared with the other two fit methods. The linear van't Hoff (15-30°C) plot obtained indicated that the thermodynamic parameters of complexation were temperature dependent for the enantiomers.
    Matched MeSH terms: Benzhydryl Compounds/chemistry*
  13. Al Balawi AN, Yusof NA, Kamaruzaman S, Mohammad F, Wasoh H, Al Abbosh KF, et al.
    Biomed Res Int, 2019;2019:7064073.
    PMID: 30868072 DOI: 10.1155/2019/7064073
    The present study has synthesized poly(4,4'-cyclohexylidene bisphenol oxalate) by the condensation of oxalyl chloride with 4,4'-cyclohexylidene bisphenol, where its efficacy was tested for the solid-phase extraction of DNA. The synthesized polymer in the form of a white powder was characterized by FTIR, TGA-DTG, SEM, and BET analysis. The study utilized solid-phase application of the resulting polymer to extract DNA. The analysis of results provided the information that the extraction efficiency is a strong dependent of polymer amount and binding buffer type. Among the three types of buffers tested, the GuHCl buffer produced the most satisfactory results in terms of yield and efficiency of extraction. Moreover, the absorbance ratio of A260/A280 in all of the samples varied from 1.682 to 1.491, thereby confirming the capability of poly(4,4'-cyclohexylidene bisphenol oxalate) to elute pure DNA. The results demonstrated an increased DNA binding capacity with respect to increased percentage of the polymer. The study has concluded that poly(bisphenol Z oxalate) can be applied as one of the potential candidates for the high efficiency extraction of DNA by means of a simple, cost-effective, and environmentally friendly approach compared to the other traditional solid-phase methods.
    Matched MeSH terms: Benzhydryl Compounds/chemistry
  14. Lim PF, Leong KH, Sim LC, Abd Aziz A, Saravanan P
    Environ Sci Pollut Res Int, 2019 Feb;26(4):3455-3464.
    PMID: 30515688 DOI: 10.1007/s11356-018-3821-1
    In this work, a sunlight-sensitive photocatalyst of nanocubic-like titanium dioxide (TiO2) and N-doped graphene quantum dots (N-GQDs) is developed through a simple hydrothermal and physical mixing method. The successful amalgamation composite photocatalyst characteristics were comprehensively scrutinized through various physical and chemical analyses. A complete removal of bisphenol A (BPA) is attained by a synthesized composite after 30 min of sunlight irradiation as compared to pure TiO2. This clearly proved the unique contribution of N-GQDs that enhanced the ability of light harvesting especially under visible light and near-infrared region. This superior characteristic enables it to maximize the absorbance in the entire solar spectrum. However, the increase of N-GQDs weight percentage has created massive oxygen vacancies that suppress the generation of active radicals. This resulted in a longer duration for a complete removal of BPA as compared to lower weight percentage of N-GQDs. Hence, this finding can offer a new insight in developing effective sunlight-sensitive photocatalysts for various complex organic pollutants degradation.
    Matched MeSH terms: Benzhydryl Compounds/chemistry*
  15. Abdulhameed AS, Wu R, Musa SA, Agha HM, ALOthman ZA, Jawad AH, et al.
    Int J Biol Macromol, 2024 Jan;256(Pt 1):128267.
    PMID: 37992917 DOI: 10.1016/j.ijbiomac.2023.128267
    In this study, chitosan/nano SiO2 (CTS/NS) was chemically modified with bisphenol A diglycidyl ether (BADGE) cross-linker-assisted hydrothermal process to create an effective adsorbent, CTS-BADGE/NS, for the removal of reactive orange 16 (RO16) dye from aquatic systems. Box-Behnken design (BBD) was used to optimize the adsorption process by varying the adsorbent dose (0.02-0.1 g/100 mL), pH (4-10), and time (20-360 min). The adsorption isotherm results indicated that the Langmuir model fits the experimental data well, suggesting that the adsorption process involves a monolayer formation of RO16 on the surface of CTS-BADGE/NS. The kinetic modeling of RO16 adsorption by CTS-BADGE/NS demonstrated that the pseudo-first-order model fits the adsorption data. CTS-BADGE/NS achieved an adsorption capacity of 97.8 mg/g for RO16 dye at optimum desirability functions of dosage 0.099 g/100 mL, solution pH of 4.44, and temperature of 25 °C. Overall, the π-π electron donor-acceptor system significantly improved the adsorption performance of the CTS-BADGE/NS. The results of the regeneration investigation demonstrate that the CTS-BADGE/NS exhibits effective adsorption of RO16, even after undergoing five consecutive cycles. The results of this study suggest that the developed CTS-BADGE/NS composite can be a promising adsorbent for water purification applications.
    Matched MeSH terms: Benzhydryl Compounds*
  16. Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, et al.
    J Am Soc Nephrol, 2024 Feb 01;35(2):202-215.
    PMID: 38082486 DOI: 10.1681/ASN.0000000000000271
    SIGNIFICANCE STATEMENT: SGLT2 inhibitors reduce risk of kidney progression, AKI, and cardiovascular disease, but the mechanisms of benefit are incompletely understood. Bioimpedance spectroscopy can estimate body water and fat mass. One quarter of the EMPA-KIDNEY bioimpedance substudy CKD population had clinically significant levels of bioimpedance-derived "Fluid Overload" at recruitment. Empagliflozin induced a prompt and sustained reduction in "Fluid Overload," irrespective of sex, diabetes, and baseline N-terminal pro B-type natriuretic peptide or eGFR. No significant effect on bioimpedance-derived fat mass was observed. The effects of SGLT2 inhibitors on body water may be one of the contributing mechanisms by which they mediate effects on cardiovascular risk.

    BACKGROUND: CKD is associated with fluid excess that can be estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co-transporter 2 inhibition on bioimpedance-derived "Fluid Overload" and adiposity in a CKD population.

    METHODS: EMPA-KIDNEY was a double-blind placebo-controlled trial of empagliflozin 10 mg once daily in patients with CKD at risk of progression. In a substudy, bioimpedance measurements were added to the main trial procedures at randomization and at 2- and 18-month follow-up visits. The substudy's primary outcome was the study-average difference in absolute "Fluid Overload" (an estimate of excess extracellular water) analyzed using a mixed model repeated measures approach.

    RESULTS: The 660 substudy participants were broadly representative of the 6609-participant trial population. Substudy mean baseline absolute "Fluid Overload" was 0.4±1.7 L. Compared with placebo, the overall mean absolute "Fluid Overload" difference among those allocated empagliflozin was -0.24 L (95% confidence interval [CI], -0.38 to -0.11), with similar sized differences at 2 and 18 months, and in prespecified subgroups. Total body water differences comprised between-group differences in extracellular water of -0.49 L (95% CI, -0.69 to -0.30, including the -0.24 L "Fluid Overload" difference) and a -0.30 L (95% CI, -0.57 to -0.03) difference in intracellular water. There was no significant effect of empagliflozin on bioimpedance-derived adipose tissue mass (-0.28 kg [95% CI, -1.41 to 0.85]). The between-group difference in weight was -0.7 kg (95% CI, -1.3 to -0.1).

    CONCLUSIONS: In a broad range of patients with CKD, empagliflozin resulted in a sustained reduction in a bioimpedance-derived estimate of fluid overload, with no statistically significant effect on fat mass.

    TRIAL REGISTRATION: Clinicaltrials.gov: NCT03594110 ; EuDRACT: 2017-002971-24 ( https://eudract.ema.europa.eu/ ).

    Matched MeSH terms: Benzhydryl Compounds/adverse effects
  17. Ahmad NA, Goh PS, Zakaria NAS, Naim R, Abdullah MS, Ismail AF, et al.
    Chemosphere, 2024 Apr;353:141108.
    PMID: 38423147 DOI: 10.1016/j.chemosphere.2024.141108
    Thin film composite (TFC) reverse osmosis (RO) membrane shows good promise for treating wastewater containing endocrine disrupting chemical (EDC) pollutants. The incorporation of functional materials with exceptional structural and physico-chemical properties offers opportunities for the membranes preparation with enhanced permselectivity and better antifouling properties. The present study aims to improve the EDC removal efficiency of TFC RO membrane using two-dimensional titania nanosheets (TNS). RO membrane was prepared by incorporating TNS in the dense layer of polyamide (PA) layer to form thin film nanocomposite (TFN) membrane. The TNS loading was varied and the influences on membrane morphology, surface hydrophilicity, surface charge, as well as water permeability and rejection of EDC were investigated. The results revealed that the inclusion of TNS in the membrane resulted in the increase of water permeability and EDC rejection. When treating the mixture of bisphenol A (BPA) and caffeine at 100 ppm feed concentration, the TFN membrane incorporated with 0.05% TNS achieved water permeability of 1.45 L/m2·h·bar, which was 38.6% higher than that of unmodified TFC membrane, while maintaining satisfactory rejection of >97%. The enhancement of water permeability for TFN membrane can be attributed to their hydrophilic surface and unique nanochannel structure created by the nanoscale interlayer spacing via staking of TiO2 nanosheets. Furthermore, the 0.05TFN membrane exhibited excellent fouling resistance towards BPA and caffeine pollutants with almost 100% flux recovery for three cycles of operations.
    Matched MeSH terms: Benzhydryl Compounds*
  18. Muhamad MS, Salim MR, Lau WJ, Hadibarata T, Yusop Z
    Environ Technol, 2016 Aug;37(15):1959-69.
    PMID: 26729509 DOI: 10.1080/09593330.2015.1137359
    Polyethersulphone (PES) membranes blended with silicon dioxide (SiO2) nanoparticles were prepared via a dry-jet wet spinning technique for the removal of bisphenol A (BPA) by adsorption mechanism. The morphology of SiO2 nanoparticles was analysed using a transmission electron microscopy and particle size distribution was also analysed. The prepared membranes were characterized by several techniques including field emission scanning electron microscopy, Fourier transform infrared spectroscopy and water contact angle. The adsorption mechanism of membrane towards BPA was evaluated by batch experiments and kinetic model. The influence of natural organic matter (NOM) in feed water on membrane BPA removal was also studied by filtration experiments. Results showed that BPA adsorption capacity as high as 53 µg/g could be achieved by the PES membrane incorporated with 2 wt% SiO2 in which the adsorption mechanism was in accordance with the pseudo-second-order kinetic model. The intraparticles diffusion model suggested that the rate limiting factor of membrane adsorption mechanism is governed by the diffusion of BPA into the membrane pores. The presence of 10 ppm NOM has reported to negatively reduce BPA removal by 24%, as it tended to compete with BPA for membrane adsorption. This work has demonstrated that PES-SiO2 membrane has the potential to eliminate trace amount of BPA from water source containing NOM.
    Matched MeSH terms: Benzhydryl Compounds/analysis; Benzhydryl Compounds/isolation & purification*; Benzhydryl Compounds/chemistry
  19. Jin M, Dang J, Paudel YN, Wang X, Wang B, Wang L, et al.
    Sci Total Environ, 2021 Jul 01;776:145963.
    PMID: 33639463 DOI: 10.1016/j.scitotenv.2021.145963
    Fluorene-9-bisphenol (BHPF) is a bisphenol A substitute, which has been introduced for the production of so-called 'bisphenol A (BPA)-free' plastics. However, it has been reported that BHPF can enter living organisms through using commercial plastic bottles and cause adverse effects. To date, the majority of the toxicologic study of BHPF focused on investigating its doses above the toxicological threshold. Here, we studied the effects of BHPF on development, locomotion, neuron differentiation of the central nervous system (CNS), and the expression of genes in the hypothalamic-pituitary-thyroid (HPT) axis in zebrafish exposed to different doses of BHPF ranging from 1/5 of LD1 to LD50 (300, 500, 750, 1500, 3000, and 4500 nM). As a result, the possible hormetic effects of BHPF on regulating the HPT axis were revealed, in which low-dose BHPF positively affected the HPT axis while this regulation was inhibited as the dose increased. Underlying mechanism investigation suggested that BHPF disrupted myelination through affecting HPT axis including related genes expression and TH levels, thus causing neurotoxic characteristics. Collectively, this study provides the full understanding of the environmental impact of BHPF and its toxicity on living organisms, highlighting a substantial and generalized ongoing dose-response relationship with great implications for the usage and risk assessment of BHPF.
    Matched MeSH terms: Benzhydryl Compounds
  20. Shehab ZN, Jamil NR, Aris AZ
    J Environ Manage, 2020 Nov 15;274:111141.
    PMID: 32818827 DOI: 10.1016/j.jenvman.2020.111141
    A simplified modelling approach for illustrating the fate of emerging pollutants can improve risk assessment of these chemicals. Once released into aquatic environments, these pollutants will interact with various substances including suspended particles, colloidal or nano particles, which will greatly influence their distribution and ultimate fate. Understanding these interactions in aquatic environments continues to be an important issue because of their possible risk. In this study, bisphenol A (BPA) in the water column of Bentong River, Malaysia, was investigated in both its soluble and colloidal phase. A spatially explicit hydrological model was established to illustrate the associated dispersion processes of colloidal-bound BPA. Modelling results demonstrated the significance of spatial detail in predicting hot spots or peak concentrations of colloidal-bound BPA in the sediment and water columns as well. The magnitude and setting of such spots were system based and depended mainly on flow conditions. The results highlighted the effects of colloidal particles' concentration and density on BPA's removal from the water column. It also demonstrated the tendency of colloidal particles to aggregate and the impact all these processes had on BPA's transport potential and fate in a river water. All scenarios showed that after 7.5-10 km mark BPA's concentration started to reach a steady state with very low concentrations which indicated that a downstream transport of colloidal-bound BPA was less likely due to minute BPA levels.
    Matched MeSH terms: Benzhydryl Compounds
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links